High-dose budesonide for early COVID-19

Lancet. 2021 Dec 11;398(10317):2147. doi: 10.1016/S0140-6736(21)02440-5.

Authors

Brian Lipworth¹, Rory Chan², Rasads Misirovs²

Affiliations

¹ Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, UK. Electronic address: b.j.lipworth@dundee.ac.uk.
² Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, UK.

No abstract available

Publication types

Letter
Comment

MeSH terms

Administration, Inhalation
Bronchodilator Agents / therapeutic use
Budesonide*
COVID-19*
Humans
SARS-CoV-2

Substances

Bronchodilator Agents
Budesonide